Udg Healthcare (UDG) Rating Reiterated by Peel Hunt
Peel Hunt restated their buy rating on shares of Udg Healthcare (LON:UDG) in a report published on Monday morning, ThisIsMoney.Co.Uk reports.
Several other equities research analysts also recently weighed in on the company. Liberum Capital reissued a buy rating and issued a GBX 884 ($11.55) price target on shares of Udg Healthcare in a report on Monday, February 4th. Barclays raised Udg Healthcare to an overweight rating and lowered their price target for the stock from GBX 770 ($10.06) to GBX 720 ($9.41) in a report on Thursday, April 4th. Finally, Numis Securities raised Udg Healthcare to a hold rating in a report on Thursday, May 16th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Udg Healthcare currently has an average rating of Buy and a consensus price target of GBX 780.57 ($10.20).
Shares of LON UDG opened at GBX 712 ($9.30) on Monday. The company has a debt-to-equity ratio of 27.53, a current ratio of 2.02 and a quick ratio of 1.80. The stock has a market capitalization of $1.77 billion and a price-to-earnings ratio of 474.67. Udg Healthcare has a fifty-two week low of GBX 545 ($7.12) and a fifty-two week high of GBX 950.50 ($12.42).
About Udg Healthcare
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services.
Recommended Story: Is the QQQ ETF safe?
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.